This report describes the development of hemolysis in eighteen glucose-6-phosphate dehydrogenase defi cient patients treated for Plasmodium vivax malaria with chloroquine and primaquine. The most frequent fi ndings accompanying hemolysis were fever and leukocytosis, in addition to anemia requiring red blood cell transfusion, and development of acute renal failure. Hemolysis in patients using primaquine is not infrequent and contributes to the morbidity of infection caused by Plasmodium vivax.
INTRODUCTION
In 2007, Brazil reported 457,659 cases of malaria, mostly in the Brazilian Amazon, with 85% caused by P. vivax infection. 1 Because of its ability to promote relapses from hypnozoites in the liver, the radical treatment of P. vivax infection requires the use of chloroquine (bloodstage schizonticidal drug) and primaquine, an 8-aminoquinoline that remains the only licensed tissue-stage schizonticidal drug. 2 The recommended dosage of chloroquine is 10 mg/ kg/day in the fi rst day followed by 7.5 mg/kg/ day in the second and third days; the dosage of primaquine is 0.5 mg/kg/day for 7 days, according to the Brazilian Antimalarial Therapy Guidelines. 3 Despite of a slightly lower effi cacy compared to the 14-day regimen (0.25 mg/kg/ day) recommended by the World Health Organization, the 7-day regimen (0.5 mg/kg/day) adopted by the Brazilian Ministry of Health leads to better compliance. 4 Primaquine however, has hemolytic anemia a notable adverse effect in patients with glucose-6-phosphate dehydrogenase (G6PD) defi ciency. 5 This is an Xlinked recessive enzymatic defect in the hexose mono-phosphate shunt, which prevents cellular damage from oxidative stress. 6 Therefore, the majority of affected cases are males. Homozygous symptomatic women are rare. The common African variant G6PD A-is usually a mild/moderate defi ciency (10−15% of normal activity in hemizygous males). In contrast, the G6PD Mediterranean variant is more severe (< 1% of normal activity). 7 In Manaus (Western Brazilian Amazon), an association between G6PD defi ciency and methemoglobinemia without signifi cant severity was detected. 8 In spite of the widespread use of primaquine in tropical areas highly endemic for P. v i v a x species, the clinical aspects of hemolysis triggered by its use are poorly described in the literature, sometimes leading to inappropriate management of these cases in the health system.
PATIENTS AND METHODS
We report a series of 18 male patients with P. v i v a x infection referred to the Tropical Medicine Foundation of Amazonas, a tertiary-care unit for infectious diseases in Manaus, Brazil, from August 2006 to August 2007. All of these patients had been treated by primaquine and developed hemolysis (indirect bilirubin > 1.0 mg/dL). They were all ultimately diagnosed with G6PD-defi ciency, by the qualitative Brewer´s test. 9 This test was repeated after 120 days in all patients with an initial negative G6PD defi ciency test because of the transitory G6PD increase related to reticulocytosis during an acute hemolytic crisis. 
DISCUSSION
In a smaller patient sample, Silva et al. detected similar clinical manifestations among G6PD-defi cient patients using primaquine in the State of Pará (Eastern Brazilian Amazon). 10 Most of our patients were already negative for Plasmodium parasites when admitted to the hospital, refl ecting an adequate response to chloroquine. The onset of symptoms related to hemolysis emerged 1-6 days after starting primaquine, supporting the need for routine follow-up of male patients during this interval, since patients are not tested routinely for G6PD defi ciency before the prescription of antimalarials in Brazil. Eleven out of the 18 patients still complained of fever, despite negative peripheral parasitemia, and 12 had leukocytosis (leukocyte count > 12,000/mm 3 ), which could be attributed to the hemolytic crisis itself. Likewise, in two American soldiers returning from Iraq who developed hemolytic anemia and leukocytosis while receiving primaquine prophylaxis for malaria, routine wide spectrum antimicrobials were not started. 11 The most clinically relevant complication in these patients was anemia, which required red blood cells transfusion in 12 of the 18 patients, leading to a substantial increase in hospitalization costs. Three patients who developed acute renal failure resolved favorably and did not require hemodialysis. One patient developed severe acute renal failure that required hemodialysis. This patient was not included in the analysis because he was lost to follow-up and the diagnosis of G6PD deficiency could not be reliably ascertained (data not shown). Therefore, acute renal failure in the tropics should raise the consideration of primaquine-triggered hemolysis in G6PD-defi cient individuals. 12 Rhabdomyolysis as the cause of acute renal failure was not investigated in our patients because none referred signifi cant myalgia.
Hemolysis in patients with P. vivax treated with primaquine, in Amazon A better characterization of hemolysis could have been achieved with the reticulocyte percentage and haptoglobin level estimates. However, these laboratorial tests are not always available in most of the malaria endemic areas.
Further studies are needed to determine the magnitude of this problem in the primary care units in malaria endemic areas, especially in Latin America where P. vivax predominates and G6PD defi ciency is estimated to be around 3%. 13 A better understanding of this hematological complication will support the development of guidelines reinforcing the correct clinical management of hemolysis developing in patients during treatment for malaria.
